Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
BMC Cardiovascular Disorders|May 29, 2016
Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trialGregory N Beatch, Brian Mangal
Circulation. Arrhythmia and Electrophysiology|August 16, 2011
A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversionChristian Torp-Pedersen, Dimitar H Raev, Garth Dickinson, et al.
Journal of Cardiac Failure|September 6, 2006
The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata StudyHoracio E Cingolani, Juan A Plastino, Eduardo M Escudero, et al.
Journal of the American College of Cardiology|January 15, 2011
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillationA John Camm, Alessandro Capucci, Stefan H Hohnloser, et al.
Statistics in Medicine|May 10, 2024
Novel non-linear models for clinical trial analysis with longitudinal data: A tutorial using SAS for both frequentist and Bayesian methodsGuoqiao Wang, Whedy Wang, Brian Mangal, et al.
Medrxiv : the Preprint Server for Health Sciences|March 4, 2025
Harnessing Greater Statistical Power: Comprehensive Evaluation of Disease Modifying Treatment Effects Across All or Multiple Post-Baseline Visits Compared to the Last Visit for Alzheimer's Disease Clinical TrialsGuoqiao Wang, Tianle Chen, John O'Gorman, et al.
Journal of the American College of Cardiology|June 14, 2008
Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF studyJoshua M Hare, Brian Mangal, Joanne Brown, et al.
Journal of Alzheimer'S Disease : JAD|June 30, 2025
Harnessing greater statistical power: Comprehensive evaluation of disease modifying treatment effects across all or multiple post-baseline visits compared to the last visit for Alzheimer's disease clinical trialsGuoqiao Wang, Tianle Chen, John O'Gorman, et al.
Clinical and Vaccine Immunology : CVI|November 13, 2015
Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 AdjuvantWilbur H Chen, Lisa A Jackson, Kathryn M Edwards, et al.
Open Forum Infectious Diseases|March 4, 2015
Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 AdjuvantWilbur H Chen, Lisa A Jackson, Kathryn M Edwards, et al.
Pageof 2